[go: up one dir, main page]

BR0210285A - Utilização de um composto, composto e composição farmacêutica - Google Patents

Utilização de um composto, composto e composição farmacêutica

Info

Publication number
BR0210285A
BR0210285A BR0210285-4A BR0210285A BR0210285A BR 0210285 A BR0210285 A BR 0210285A BR 0210285 A BR0210285 A BR 0210285A BR 0210285 A BR0210285 A BR 0210285A
Authority
BR
Brazil
Prior art keywords
compound
optionally substituted
radical
pharmaceutical composition
alkyl
Prior art date
Application number
BR0210285-4A
Other languages
English (en)
Inventor
Dennis Bigg
Jacques Pommier
Anne-Marie Liberatore
Original Assignee
Sod Conseils Rech Applic
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sod Conseils Rech Applic filed Critical Sod Conseils Rech Applic
Publication of BR0210285A publication Critical patent/BR0210285A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/64—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms, e.g. histidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4174—Arylalkylimidazoles, e.g. oxymetazolin, naphazoline, miconazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/06—Anti-spasmodics, e.g. drugs for colics, esophagic dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Cardiology (AREA)
  • Rheumatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Hospice & Palliative Care (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Networks Using Active Elements (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Detergent Compositions (AREA)
  • Control Of Transmission Device (AREA)
  • Molds, Cores, And Manufacturing Methods Thereof (AREA)

Abstract

"UTILIZAçãO DE UM COMPOSTO, COMPOSTO E COMPOSIçãO FARMACêUTICA". De acordo com a invenção, os compostos de fórmula geral (I) na qual R^ 1^ representa um radical alquila, cicloalquilalquila ou aralquila eventualmente substituído no grupo arila; R^ 2^ representa um radical fenila eventualmente substituído ou ainda R^ 2^ representa um radical bifenila eventualmente substituído; R^ 3^ representa um átomo de hidrogênio ou um radical alquila e os sais farmaceuticamente aceitáveis destes últimos, podem ser utilizados para preparar um medicamento destinado a modular os canais sódicos e especialmente a tratar a dor (por exemplo a dor de origem neuropática), a epilepsia, perturbações ligadas à neurodegeneração ou perturbações bipolares.
BR0210285-4A 2001-06-14 2002-06-14 Utilização de um composto, composto e composição farmacêutica BR0210285A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR0107820A FR2825926A1 (fr) 2001-06-14 2001-06-14 Derives d'imidazoles modulant les canaux sodiques
PCT/FR2002/002039 WO2002102375A2 (fr) 2001-06-14 2002-06-14 Derives d'imidazoles modulant les canaux sodiques

Publications (1)

Publication Number Publication Date
BR0210285A true BR0210285A (pt) 2004-06-29

Family

ID=8864329

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0210285-4A BR0210285A (pt) 2001-06-14 2002-06-14 Utilização de um composto, composto e composição farmacêutica

Country Status (21)

Country Link
US (3) US7157483B2 (pt)
EP (1) EP1401432B1 (pt)
JP (1) JP2005500297A (pt)
KR (1) KR20040030672A (pt)
CN (1) CN1535148A (pt)
AT (1) ATE304354T1 (pt)
BR (1) BR0210285A (pt)
CA (1) CA2449916A1 (pt)
CZ (1) CZ297321B6 (pt)
DE (1) DE60206171T2 (pt)
DK (1) DK1401432T3 (pt)
ES (1) ES2249595T3 (pt)
FR (1) FR2825926A1 (pt)
HU (1) HUP0400195A3 (pt)
IS (1) IS2367B (pt)
MX (1) MXPA03011508A (pt)
NO (1) NO20035553D0 (pt)
NZ (1) NZ529741A (pt)
PL (1) PL366722A1 (pt)
RU (1) RU2296565C2 (pt)
WO (1) WO2002102375A2 (pt)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2004210711B2 (en) * 2003-02-12 2010-07-08 Transtech Pharma, Inc. Substituted azole derivatives as therapeutic agents
ZA200507752B (en) * 2003-03-28 2007-01-31 Threshold Pharmaceuticals Inc Compositions and methods for treating cancer
BRPI0416639A (pt) * 2003-11-19 2007-01-16 Metabasis Therapeutics Inc tiromiméticos contendo fósforo
AU2006249350B2 (en) 2003-11-19 2012-02-16 Metabasis Therapeutics, Inc. Thyromimetics for the treatment of fatty liver diseases
CN102746336B (zh) 2005-06-29 2015-08-19 施瑞修德制药公司 氨基磷酸酯烷化剂前体药物
AU2006322844A1 (en) * 2005-12-07 2007-06-14 Ramot At Tel Aviv University Ltd. Chemical derivatives of jasmonate, pharmaceutical compositions and methods of use thereof
US8247439B2 (en) * 2005-12-07 2012-08-21 Sepal Pharma Ltd. Jasmonate derivatives, pharmaceutical compositions and methods of use thereof
US9284274B2 (en) 2005-12-07 2016-03-15 Ramot At Tel-Aviv University Ltd. Chemical derivatives of jasmonate, pharmaceutical compositions and methods of use thereof
EP2114157B1 (en) 2006-12-26 2021-05-26 ImmunoGenesis, Inc. Phosphoramidate alkylator prodrug for the treatment of cancer
US7883898B2 (en) * 2007-05-07 2011-02-08 General Electric Company Method and apparatus for measuring pH of low alkalinity solutions
US8188080B2 (en) * 2007-10-17 2012-05-29 Sanford-Burnham Medical Research Institute VHR protein tyrosine phosphatase inhibitors, compositions and methods of use
US8815892B2 (en) 2008-03-25 2014-08-26 Affectis Pharmaceuticals Ag P2X7R antagonists and their use
EP2105164B1 (en) * 2008-03-25 2011-01-12 Affectis Pharmaceuticals AG Novel P2X7R antagonists and their use
KR101602985B1 (ko) * 2008-10-06 2016-03-11 시코쿠가세이고교가부시키가이샤 2-벤질-4-(2,4-디클로로페닐)-5-메틸이미다졸 화합물
US9284252B2 (en) 2009-06-09 2016-03-15 Sepal Pharma Ltd. Use of jasmonate ester derivatives for treating benign hyperproliferative skin disorders
JP5368244B2 (ja) * 2009-10-14 2013-12-18 四国化成工業株式会社 ２−（２，４−ジクロロベンジル）−４−アリール−５−メチルイミダゾール化合物
JP5368263B2 (ja) * 2009-11-04 2013-12-18 四国化成工業株式会社 ４−（２，４−ジクロロフェニル）−５−メチルイミダゾール化合物
JP5368271B2 (ja) * 2009-11-20 2013-12-18 四国化成工業株式会社 ４−（４−ビフェニリル）−２−（２，４−ジクロロベンジル）イミダゾールおよび表面処理液
CN110198719A (zh) 2016-11-21 2019-09-03 维京治疗公司 治疗糖原贮积病的方法
KR102600115B1 (ko) 2017-06-05 2023-11-09 바이킹 테라퓨틱스 인코포레이티드 섬유증 치료를 위한 조성물
AU2019238090B2 (en) 2018-03-22 2024-08-01 Viking Therapeutics, Inc. Crystalline forms and methods of producing crystalline forms of a compound
US12102646B2 (en) 2018-12-05 2024-10-01 Viking Therapeutics, Inc. Compositions for the treatment of fibrosis and inflammation
CN120513089A (zh) * 2022-10-31 2025-08-19 Genep股份有限公司 作为钠通道抑制剂的咪唑化合物及其用途
WO2025231324A1 (en) * 2024-05-02 2025-11-06 Genep Inc. Imidazole compounds and their use as sodium channel inhibitors

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1046248A (en) * 1962-08-02 1966-10-19 Benger Lab Ltd Substituted imidazoles
AU518569B2 (en) * 1979-08-07 1981-10-08 Farmos-Yhtyma Oy 4-benzyl- and 4-benzoyl imidazole derivatives
CN1093535C (zh) * 1994-09-26 2002-10-30 盐野义制药株式会社 咪唑衍生物
CN1284066A (zh) * 1997-12-04 2001-02-14 阿勒根销售公司 对α2B或2B/2C肾上腺素能受体具有激动剂样活性的取代咪唑衍生物
US6003118A (en) * 1997-12-16 1999-12-14 Acer Laboratories Inc. Method and apparatus for synchronizing clock distribution of a data processing system
ATE467620T1 (de) * 1999-03-26 2010-05-15 Euro Celtique Sa Arylsubstituierte pyrazole, imidazole, oxazole, thiazole und pyrrole, sowie deren verwendung
AR024077A1 (es) * 1999-05-25 2002-09-04 Smithkline Beecham Corp Compuestos antibacterianos
TWI283577B (en) * 1999-10-11 2007-07-11 Sod Conseils Rech Applic Pharmaceutical composition of imidazole derivatives acting as modulators of sodium channels and the use thereof
WO2001044201A1 (en) * 1999-12-16 2001-06-21 Schering Corporation Substituted imidazole neuropeptide y y5 receptor antagonists

Also Published As

Publication number Publication date
US7157483B2 (en) 2007-01-02
HUP0400195A3 (en) 2004-10-28
ATE304354T1 (de) 2005-09-15
US20040198792A1 (en) 2004-10-07
CN1535148A (zh) 2004-10-06
MXPA03011508A (es) 2004-03-18
HUP0400195A2 (hu) 2004-07-28
US20060069146A1 (en) 2006-03-30
CA2449916A1 (fr) 2002-12-27
DE60206171D1 (de) 2005-10-20
DK1401432T3 (da) 2006-02-06
NZ529741A (en) 2006-10-27
FR2825926A1 (fr) 2002-12-20
US7402602B2 (en) 2008-07-22
IS7067A (is) 2003-12-08
RU2004100843A (ru) 2005-04-10
CZ297321B6 (cs) 2006-11-15
EP1401432B1 (fr) 2005-09-14
US20070099975A1 (en) 2007-05-03
RU2296565C2 (ru) 2007-04-10
DE60206171T2 (de) 2006-06-22
NO20035553D0 (no) 2003-12-12
KR20040030672A (ko) 2004-04-09
JP2005500297A (ja) 2005-01-06
WO2002102375A2 (fr) 2002-12-27
IS2367B (is) 2008-06-15
WO2002102375A3 (fr) 2003-09-25
PL366722A1 (en) 2005-02-07
CZ20033550A3 (cs) 2005-05-18
EP1401432A2 (fr) 2004-03-31
ES2249595T3 (es) 2006-04-01

Similar Documents

Publication Publication Date Title
BR0210285A (pt) Utilização de um composto, composto e composição farmacêutica
BR9714787A (pt) Compostos de 4- fenilpiperidina e processo para sua preparação
BR0109356A (pt) Inibidores de protease
IL120584A (en) 1,2-diphenylpyrrole derivatives, use thereof for the manufacture of a medicament and pharmaceutical compositions containing the same
BR0213242A (pt) Composto ou um seu sal ou solvato, composto e seus sais de adição de ácido fisiologicamente aceitáveis, composição farmacêutica, método de tratamento de um ou mais distúrbios, uso de um composto, e, processo de preparação de um composto
BR9713465A (pt) Inibidores metalotprotease de amina cìclica sibstituìda
BRPI0412219A (pt) composto, sal farmaceuticamente aceitável de um composto, composição farmacêutica, método para regular a transdução de sinal método para tratamento ou prevenção de uma doença
BR9916488A (pt) Inibidores de protease
BR0212378A (pt) Inibidores de 17beta-hidroxiesteróide desidrogenase tipo 3 para o tratamento de doenças dependentes de androgênio
BR9813926A (pt) Substituição de bioisóstero de catecol por indazol em compostos terapeuticamente ativos
ES555653A0 (es) Un procedimiento para preparar compuestos imidazoheterociclicos
BR9908545A (pt) Derivado de piperidina, processo para a preparação do mesmo, composto, processo para a preparação do mesmo, e, composição farmacêutica
DE69529670D1 (de) Oxazolidinon derivate und diese enthaltende pharmazeutische zusammensetzungen
BR9804437A (pt) Compostos para a osteoporose
BR9809062A (pt) Inibidores da metaloproteinase, composições farmacêuticas comtendo os mesmos e seus usos farmacêuticos
BR9811521A (pt) Composição para tratar ou impedir a glomerulopatia
BR0309188A (pt) Compostos pirazolo como agentes antiinflamatórios e analgésicos
BRPI0407695A (pt) compostos, processo para a preparação de um composto, composições farmacêuticas que compreendem o composto, utilização dos compostos e processo de tratamento para diabetes do tipo 2
BRPI0410316A (pt) composto, composição farmacêutica, uso dos compostos, e, método de tratamento de distúrbios mediados por vr1 e para o tratamento de distúrbios de dores
ES2038172T3 (es) Procedimiento para preparar carboxamidas heterociclicas.
BR0212069A (pt) Agentes antidiabéticos orais
BR0113590A (pt) 7-oxo-piridopirimidinas
BR0309305A (pt) Compostos de imidazol como agentes antiinflamatórios e analgésicos
FR2800735B1 (fr) Nouvelles aralkyle-1,2-diamines possedant une activite calcimimetique et leur mode de preparation
BR9805031A (pt) Compostos de naftaleno, processo para sua preparação e composições farmacêuticas contendo os mesmos.

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 9A ANUIDADE(S).

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2108 DE 31/05/2011.